Advances in diagnosis and treatment of metabolic-associated fatty liver disease
Non-alcoholic fatty liver disease(NAFLD)is a clinical syndrome that exhibits similar his-topathological changes in the liver as alcoholic liver disease,despite the absence of a history of excessive alco-hol consumption in patients.It encompasses a range of conditions,including simple fatty liver,non-alcoholic steatohepatitis(NASH),fatty liver cirrhosis,and hepatocellular carcinoma.NASH represents a critical stage in the progression of this disease.Such diseases have been officially named as metabolic-associated fatty liver disease,and there is a general consensus that the progression of this disease can be accurately described by its activity and degree of fibrosis.The emergence of liver fibrosis has asignificant impact on the prognosis of these patients.Without timely diagnosis and treatment,the condition may gradually deteriorate,leading to liv-er cirrhosis and its associated complications,and there is even a possibility of developing hepatocellular carci-noma.Effective prevention and treatment of MAFLD have the potential to further halt the progression of chronic liver diseases and reduce the risks of liver cirrhosis,liver-related disabilities,and fatalities.
万方数据
维普
